developed AAV‐loaded microneedles for ischemic heart disease treatment.[94] Fluorescent labeling results verified the successful gene transfection with uniform and precise distribution of AAV at injected cardiac regions, which proved the feasibility of AAV‐VEGF‐loaded microneedles (MN‐AAV‐VEGF). The gene discussed is VEGFA; the disease is coronary artery disorder.